The award is a reputational milestone but does not alter the company's clinical or financial trajectory. Monitor upcoming clinical data readouts and capital needs for the clinical-stage pipeline.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Oct 30 $2.93entry
- T+1 · 15d ago −0.34%α +0.14% · $2.92
- T+5 · 11d ago +2.39%α +5.09% · $3.00
- T+11 · todayOpen
- T+20 · in 13d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced it received the 2026 International Prix Galien Award for its AI-Immunology platform as best digital health solution. This is a prestigious recognition but does not include any financial data, revenue, or changes to the company's pipeline or financial outlook.
Key Facts
- Evaxion awarded the 2026 International Prix Galien Award for AI-Immunology as best digital health solution.
- First time a Danish company has won this international award.
- The award is presented every two years and is often regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
- Evaxion previously won the Prix Galien UK Award in June 2026 and the Nordic/European/Middle Eastern award in December 2025.
- No financial results, guidance, or material business changes were disclosed in this filing.
Financial Impact
No financial impact stated; the filing contains no revenue, earnings, or financial data.
Risk Factors
- No financial information provided; the company remains a clinical-stage biotech with no approved products and likely ongoing capital requirements.
- Forward-looking statements highlight risks including need for additional capital and dependence on clinical trial success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006992 |
| Document: f6k_103026.htm | 0001171843-26-006992 |
| Document: 0001171843-26-006992-index-headers.html | 0001171843-26-006992 |
| Document: 0001171843-26-006992-index.html | 0001171843-26-006992 |
| Document: 0001171843-26-006992.txt | 0001171843-26-006992 |
| Earnings Context (Synthetic; results releases only) | 0001171843-26-006992 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Viewing Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers